ΠΠΈΡΠ΅ΡΠ°ΡΡΡΠ°.
ΠΠΈΠΌΠ΅ΡΡΠ»ΠΈΠ΄: ΠΎΡΠ½ΠΎΠ²Π½ΡΠ΅ ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΡ Π΄Π΅ΠΉΡΡΠ²ΠΈΡ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΡ
Barracchini A., Franceschini N., Amicosante G. et al. Can non-steroidal anti-inflammatory drugs act as metalloproteinase modulators? An in-vitro study of inhibition of collagenase activity. J. Pharm. Pharmacol. 1998; 50: 1417β23. Conforti A., Leone R., Moretti U., Mozzo F., Velo G. Adverse drug reactions related to the use of NSAIDs with a focus on nimesulide: results of spontaneous reporting… Π§ΠΈΡΠ°ΡΡ Π΅ΡΡ >
ΠΠΈΡΠ΅ΡΠ°ΡΡΡΠ°. ΠΠΈΠΌΠ΅ΡΡΠ»ΠΈΠ΄: ΠΎΡΠ½ΠΎΠ²Π½ΡΠ΅ ΠΌΠ΅Ρ Π°Π½ΠΈΠ·ΠΌΡ Π΄Π΅ΠΉΡΡΠ²ΠΈΡ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΡ (ΡΠ΅ΡΠ΅ΡΠ°Ρ, ΠΊΡΡΡΠΎΠ²Π°Ρ, Π΄ΠΈΠΏΠ»ΠΎΠΌ, ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½Π°Ρ)
1. ΠΠ°ΡΠΎΠ½ΠΎΠ² Π. Π. ΠΡΠΎΡΠΈΠ²ΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½Π°Ρ ΡΠ΅ΡΠ°ΠΏΠΈΡ ΡΠ΅Π²ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ Π±ΠΎΠ»Π΅Π·Π½Π΅ΠΉ. Π., Π-Π‘ΠΈΡΠΈ 1996; 60−72.
2. Flower R. The roles of COX-1 and COX-2: implications for NSAID development. Curr. Opin. Rheum. 1996; 9(Suppl. 1):S9-S13.
3. Vane G.R., Bakchle Y.S. Bolting R.M. Cyclooxygenase 1 and 2. Ann. Rev. Pharmacol. Toxicol. 1998; 38:97−120.
4. ΠΠ°ΡΠΎΠ½ΠΎΠ² Π. Π. ΠΠ΅ΡΡΠ΅ΡΠΎΠΈΠ΄Π½ΡΠ΅ ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΡ (ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Ρ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ Π² ΠΌΠ΅Π΄ΠΈΡΠΈΠ½Π΅). Π., 2000, 143.
5. Bunczak-Reeh M.A., Hargreaves K.M. Effect of inflammation on the delivery og drugs to dental pulp. J Endodonitics 1998; 24: 822−824.
6. Bernareggi A. Pharmacokinetics of nimesulide. Clin Pharm 1998; 35(4); 247−274.
7. Bianchi M., Broggini M. Anti-hyperalgesic effects of nimesulide: Studies in rats and humans. Intern. J. Clin. Pract. 2002; (suppl 128):11−19.
8. Ragot J.P., Monti T., Macciocchi A. Controlled clinical investigation of acute analgesic activity of nimesulide in pain after oral surgery. Drugs. 1993; 46 (suppl 1):162−167.
9. Pulkinnen M.O. Nimesulide in dysmenorrhoea. Drugs 1993; 46 (suppl.1): 129−33.
10. ΠΡΠ΄Π°Π΅Π²Π° Π€. Π., ΠΠ°ΡΡΠΊΠΎΠ²Π° Π. Π., ΠΠ°ΡΠΎΠ½ΠΎΠ²Π° Π. Π. Π‘ΡΠ°Π²Π½Π΅Π½ΠΈΠ΅ ΡΠΊΠΎΡΠΎΡΡΠΈ Π½Π°ΡΡΡΠΏΠ»Π΅Π½ΠΈΡ ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΠΈ Π°Π½Π°Π»ΡΠ³Π΅ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΡΡΠ΅ΠΊΡΠΎΠ² ΡΠ°Π±Π»Π΅ΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ Π½ΠΈΠΌΠ΅ΡΡΠ»ΠΈΠ΄ΠΎΠ² ΠΈ Π΄ΠΈΠΊΠ»ΠΎΡΠ΅Π½Π°ΠΊΠ° Π½Π°ΡΡΠΈΡ ΠΏΡΠΈ ΠΏΠΎΠ΄Π°Π³ΡΠΈΡΠ΅ΡΠΊΠΎΠΌ Π°ΡΡΡΠΈΡΠ΅ (ΡΠ°Π½Π΄ΠΎΠΌΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅). ΠΠ°ΡΡΠ½ΠΎ-ΠΏΡΠ°ΠΊΡΠΈΡ. Π Π΅Π²ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡ, 2008, 1, 55−59.
11. Boelsterli U. Nimesulide and hepatic adverse affects: roles of reactive metabolites and host factors. Int. J. Clin. Pract., 2002 supl., 128, 30−36.
12. ΠΠ°ΡΠ°ΡΠ΅Π΅Π² Π. Π., ΠΠ°ΡΡΠΊΠΎΠ²Π° Π. Π. ΠΠ΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΡ Π½ΠΈΠΌΠ΅ΡΡΠ»ΠΈΠ΄Π°: ΡΠΌΠΎΡΠΈΠΈ ΠΈΠ»ΠΈ Π²Π·Π²Π΅ΡΠ΅Π½Π½Π°Ρ ΠΎΡΠ΅Π½ΠΊΠ°. Consilium medicum. 2007, 2, 60−64.
13. Traversa G., Bianchi C., Da Cas R. et al. Cohort study of hepatotoxity associated with nimesulide and other non-steroidal anti-inflammatory drugs. BMJ, 2003, 327, 18−22.
14. European Medicines Evaluation Agency, Committee for Proprietary Medicinal Products. Nimesulide containing medicinal products. CPMP/1724/04. htpp://www.emea.eu.int.
15. ΠΠ°ΡΠ°ΡΠ΅Π΅Π² Π. Π. ΠΠ°ΡΡΡΠΎΠ΄ΡΠΎΠ΄Π΅Π½Π°Π»ΡΠ½Π°Ρ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΡ ΡΠ΅Π»Π΅ΠΊΡΠΈΠ²Π½ΡΡ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠΎΠ² ΡΠΈΠΊΠ»ΠΎΠΎΠΊΡΠΈΠ³Π΅Π½Π°Π·Ρ-2: ΠΏΡΠΎΠ²Π΅ΡΠΊΠ° ΠΏΡΠ°ΠΊΡΠΈΠΊΠΎΠΉ. Π’Π΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈΠΉ Π°ΡΡ ΠΈΠ² 2005; 5, 69−72.
16. Conforti A., Leone R., Moretti U., Mozzo F., Velo G. Adverse drug reactions related to the use of NSAIDs with a focus on nimesulide: results of spontaneous reporting from a Northen Italian area. Drug Saf., 2001, 24, 1081−1090.
17. Bradbury F. How important is the role of the physician in the correct use of a drug? An observational cohort study in gereral practice. Int. J. Clin. Pract., 2004, supl. 144, 27−32.
19. ΠΠ°ΡΠ°ΡΠ΅Π΅Π² Π. Π., ΠΠ°ΡΠ°ΡΠ΅Π΅Π² Π. Π., ΠΡΡΠΈΡ ΠΈΠ½Π° Π. Π. ΠΈ Π΄Ρ. ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΡ ΠΌΠΎΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π²ΡΡΠΎΠΊΠΈΠΌΠΈ Π΄ΠΎΠ·Π°ΠΌΠΈ ΠΠΠΠ ΠΏΡΠΈ ΡΠ°Π½Π½Π΅ΠΌ ΡΠ΅ΠΌΠ°ΡΠΎΠΈΠ΄Π½ΠΎΠΌ Π°ΡΡΡΠΈΡΠ΅ (ΠΎΡΠΊΡΡΡΠΎΠ΅ ΡΠ°Π½Π΄ΠΎΠΌΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ΅ ΠΊΠΎΠ½ΡΡΠΎΠ»ΠΈΡΡΠ΅ΠΌΠΎΠ΅ 4-Π½Π΅Π΄Π΅Π»ΡΠ½ΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Π²ΡΡΠΎΠΊΠΈΡ ΠΈ ΡΡΠ΅Π΄Π½Π΅ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈΡ Π΄ΠΎΠ· Π½ΠΈΠΌΠ΅ΡΡΠ»ΠΈΠ΄Π° ΠΈ Π΄ΠΈΠΊΠ»ΠΎΡΠ΅Π½Π°ΠΊΠ° ΠΏΡΠΈ ΡΠ°Π½Π½Π΅ΠΌ Π°ΡΡΡΠΈΡΠ΅: ΠΏΡΠ΅Π΄Π²Π°ΡΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ Π΄Π°Π½Π½ΡΠ΅. Π ΡΡΡΠΊΠΈΠΉ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΈΠΉ ΠΆΡΡΠ½Π°Π» 2006; 25:1805−1809.
20. Π§ΠΈΡΠ°ΡΠΎΠ²Π° Π. Π., ΠΠΌΠ°ΠΌΠ΅ΡΠ΄ΠΈΠ½ΠΎΠ²Π° Π. Π ., ΠΠ°ΡΠΎΠ½ΠΎΠ² Π. Π. ΠΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΡΠ΅Π»Π΅ΠΊΡΠΈΠ²Π½ΡΡ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠΎΠ² Π¦ΠΠ-2 Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΠΌΠΈ ΡΡΡΡΠ°Π²ΠΎΠ² ΠΈ Π°ΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΠ΅ΠΉ. ΠΠ°ΡΡΠ½ΠΎ-ΠΏΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΡΠ΅Π²ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡ 2004; 2:27−40.
21. ΠΠ°ΡΡΠΊΠΎΠ²Π° Π. Π., ΠΠ°ΡΠΎΠ½ΠΎΠ²Π° Π. Π., Π¦Π°ΠΏΠΈΠ½Π° Π’. Π. ΠΈ Π΄Ρ. ΠΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ Π½ΠΈΠΌΠ΅ΡΡΠ»ΠΈΠ΄Π° (Π½ΠΈΠΌΠ΅ΡΠΈΠ»Π°) Ρ Π±ΠΎΠ»ΡΠ½ΡΡ ΠΏΠΎΠ΄Π°Π³ΡΠΈΡΠ΅ΡΠΊΠΈΠΌ Π°ΡΡΡΠΈΡΠΎΠΌ. ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½Π° 2004; 12:49−54.
22. ΠΠ°Π·ΡΡΠΎΠ² Π. Π. ΠΡΡΠ΅Ρ ΠΎ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ°Ρ ΠΏΠΈΠ»ΠΎΡΠ½ΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΏΠΎ ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΎΡΠ΅Π½ΠΊΠ΅ Π²Π»ΠΈΡΠ½ΠΈΡ ΠΠ°ΠΉΠ·Π° (Π½ΠΈΠΌΠ΅ΡΡΠ»ΠΈΠ΄) ΠΈ Π΄ΠΈΠΊΠ»ΠΎΡΠ΅Π½Π°ΠΊΠ° Π½Π° Π³Π΅ΠΌΠΎΠ΄ΠΈΠ½Π°ΠΌΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ ΠΎΡΡΠ΅ΠΎΠ°ΡΡΡΠΎΠ·ΠΎΠΌ Π² ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠΈ Ρ ΡΡΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π°ΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΠ΅ΠΉ.
23. Davis R., Brodgen R.N. Nimesulide: An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1994; 48: 431−54.
24. Senna G.E., Passalacqua G., Dama A. et al. Nimesulide and meloxicam are a safe alternative drugs for patients intolerant to nonsteroidal anti-inflammatory drugs. Eur. Ann. Allergy Clin. Immunol. 2003; 35(10):393−396.
25. Tavares I.A., Bishai P.M., Bennet A. Activity of nimesulide on constitutive and inducible cyclo-oxygenases. Arzneim-Forsch/Drug Res. 1995; 45:1093−1096.
26. Panara M.R., Padovano R., Sciulli M. et al. Effects of nimesulide on constitutive and inducible prostanoid biosynthesis in human beings. Clin. Pharmacol. Ther. 1998; 63: 672−81.
27. Pelletier J.P., Mineau F., Fernandes J.C. et al. Two NSAIDs, nimesulide and naproxen, can reduce the synthesis of urokinase and IL-6 while increasing PAI-1, in human OA synovial fibroblasts. Clin. Exp. Rheumatol. 1997; 15: 393−398.
28. Rossoni G., Berti F., Buschi A., Villa L.M., Della Bella D. New data concerning the antianaphylactic and antihistaminic activity of nimesulide. Drugs 1993; 46(suppl.1): 22−28.
29. Pelletier J.P., Di Battista J.A., Zhang M., et al. Effect of nimesulide on glucocorticoid receptor activity in human synovial fibroblasts. Rheumatology 1999; 38 (suppl.1): 11−13.
30. Barracchini A., Franceschini N., Amicosante G. et al. Can non-steroidal anti-inflammatory drugs act as metalloproteinase modulators? An in-vitro study of inhibition of collagenase activity. J. Pharm. Pharmacol. 1998; 50: 1417−23.
31. Hentrotin Y.E., Labasse A.H., Simonis P.E. et al. Effects of nimesulide and sodium diclofenac on interleukin-6, interleukin-8, proteoglycans and prostaglandin E2 production by human articular chondrocytes in vitro. Clin. Exp. Rheumatol. 1999; 17:151−60.
32. Omololu B., Alonge T.O., Ogunlade S.O., Aduroja O.O. Double-blind clinical trial comparing the safety and efficacy of nimesulide (100 mg) and diclofenac in osteoarthrosis of the hip and knee joints. West Afr. Med. 2005; 24(2): 128−133.
33. Kriegel W., Korff K.J., Ehrlich J.C., et al. Double-blind study comparing the long-term efficacy of the COX-2 inhibitior nimesulide and naproxen in patients with osteoarthritis. Int. J. Clin. Pract. 2001; 55(8): 510−514.
34. Herrera J.A., Gonzalez M. Comparative evaluation of the effectiveness and tolerability of nimesulide versus rofecoxib taken once a day in the treatment of patients with knee osteoarthritis. Am. J. Ther. 2003; 10(6):468−472.
35. Bennett A. Nimesulide a well established cyclooxygenase-2 inhibitor with many other pharmacological properties relevant to inflammatory diseases. In: Therapeutic Roles of Selective COX-2 Inhibitors. Editors Vein J.R., Botting R.M., William Harvey Press: 524−540.